{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film", "query": { "intervention": "Placebo film" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 309, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T00:14:06.287Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02966834", "title": "Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cholestasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "GSK2330672", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 147, "start_date": "2017-01-11", "completion_date": "2020-04-15", "has_results": true, "last_update_posted_date": "2021-05-04", "last_synced_at": "2026-09-26T00:14:06.287Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Sacramento, California • Miami, Florida + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Novi", "state": "Michigan" }, { "city": "Manhasset", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02966834" }, { "nct_id": "NCT02382016", "title": "PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Portopulmonary Hypertension" ], "interventions": [ { "name": "Macitentan", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Actelion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2015-06-23", "completion_date": "2018-10-31", "has_results": true, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-09-26T00:14:06.287Z", "location_count": 29, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02382016" }, { "nct_id": "NCT02158936", "title": "A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Thrombocytopaenia" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 356, "start_date": "2014-06-10", "completion_date": "2016-04-30", "has_results": true, "last_update_posted_date": "2017-12-12", "last_synced_at": "2026-09-26T00:14:06.287Z", "location_count": 10, "location_summary": "Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Anderson", "state": "Indiana" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02158936" }, { "nct_id": "NCT00134563", "title": "Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Teriflunomide", "type": "DRUG" }, { "name": "Placebo (for teriflunomide)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1088, "start_date": "2004-09", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2013-01-04", "last_synced_at": "2026-09-26T00:14:06.287Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134563" }, { "nct_id": "NCT05182840", "title": "A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Disease, Chronic" ], "interventions": [ { "name": "BI 690517", "type": "DRUG" }, { "name": "Placebo to BI 690517", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" }, { "name": "Placebo to empagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 714, "start_date": "2022-01-11", "completion_date": "2023-07-10", "has_results": true, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-09-26T00:14:06.287Z", "location_count": 41, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Canyon Country", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05182840" }, { "nct_id": "NCT03086343", "title": "A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo for upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 657, "start_date": "2017-05-09", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-09-26T00:14:06.287Z", "location_count": 44, "location_summary": "Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03086343" }, { "nct_id": "NCT00902174", "title": "Imatinib (QTI571) in Pulmonary Arterial Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2009-09", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-09-26T00:14:06.287Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00902174" }, { "nct_id": "NCT05321082", "title": "A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Diseases, Interstitial" ], "interventions": [ { "name": "BI 1015550", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1178, "start_date": "2022-11-16", "completion_date": "2025-04-14", "has_results": true, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-09-26T00:14:06.287Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05321082" }, { "nct_id": "NCT04566601", "title": "A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Personality Disorder" ], "interventions": [ { "name": "BI 1358894", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 390, "start_date": "2020-11-13", "completion_date": "2023-01-25", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-09-26T00:14:06.287Z", "location_count": 16, "location_summary": "Anaheim, California • Temecula, California • Upland, California + 13 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Temecula", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566601" }, { "nct_id": "NCT01170962", "title": "Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "BMS-790052", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 512, "start_date": "2010-08", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-09-26T00:14:06.287Z", "location_count": 35, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01170962" } ] }